Literature DB >> 8513856

Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study.

D Baettig1, G Bondolfi, S Montaldi, M Amey, P Baumann.   

Abstract

In a depressed patient, the addition of citalopram 40-60 mg per day to treatment with amitriptyline 75 mg per day had no effect on the plasma levels of amitriptyline and nortriptyline, but it led to clinical improvement without the appearance of adverse effects. This and similar findings in four other patients comedicated with citalopram and amitriptyline (2 patients), clomipramine or maprotiline suggest that citalopram differs from other selective serotonin reuptake inhibitors, such as fluvoxamine and fluoxetine, which have been shown to increase tricyclic antidepressant plasma levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513856     DOI: 10.1007/BF00316483

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Inhibitors of imipramine metabolism by human liver microsomes.

Authors:  E Skjelbo; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; E Skjelbo
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

3.  Fluvoxamine-tricyclic antidepressant interaction. An accidental finding.

Authors:  G Bertschy; S Vandel; B Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Serum fluoxetine and norfluoxetine concentrations and antidepressant response.

Authors:  M W Kelly; P J Perry; S G Holstad; M J Garvey
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

5.  Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine.

Authors:  J M Downs; A D Downs; T L Rosenthal; N Deal; H S Akiskal
Journal:  J Clin Psychiatry       Date:  1989-06       Impact factor: 4.384

6.  Elevated antidepressant plasma levels after addition of fluoxetine.

Authors:  A B Aranow; J I Hudson; H G Pope; T A Grady; T A Laage; I R Bell; J O Cole
Journal:  Am J Psychiatry       Date:  1989-07       Impact factor: 18.112

7.  Interaction of fluoxetine with tricyclic antidepressants.

Authors:  D A Vaughan
Journal:  Am J Psychiatry       Date:  1988-11       Impact factor: 18.112

Review 8.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

9.  The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.

Authors:  E Skjelbo; K Brøsen; J Hallas; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1991-01       Impact factor: 6.875

10.  Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.

Authors:  P Baumann; M Jonzier-Perey; L Koeb; A Küpfer; D Tinguely; J Schöpf
Journal:  Int Clin Psychopharmacol       Date:  1986-04       Impact factor: 1.659

View more
  5 in total

Review 1.  The clinical pharmacokinetics of escitalopram.

Authors:  Niranjan Rao
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 4.  Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.

Authors:  B A Sproule; C A Naranjo; K E Brenmer; P C Hassan
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 5.  Citalopram--a review of pharmacological and clinical effects.

Authors:  K Bezchlibnyk-Butler; I Aleksic; S H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.